Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01

A. Bardia; K. Kalinsky; J. Tsurutani; E.P. Hamilton; S. Johnston; J. Sohn; K.H. Park; Y.H. Park; S-A. Im; K.S. Lee; D. Dastur; V. Haddad; S. Khan; B. Xu; B. Pistilli; H.S. Rugo

doi:10.1016/j.annonc.2022.07.1858

YUHSpace

BROWSE

0 140

Cited 0 times in

Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01

Authors: A. Bardia ; K. Kalinsky ; J. Tsurutani ; E.P. Hamilton ; S. Johnston ; J. Sohn ; K.H. Park ; Y.H. Park ; S-A. Im ; K.S. Lee ; D. Dastur ; V. Haddad ; S. Khan ; B. Xu ; B. Pistilli ; H.S. Rugo